Fig. 1From: Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation StudyFlow chart of patients enrolled in this clinical trialBack to article page